First vaccinations have now begun in Mali in a phase III trial of a malaria vaccine developed at the University of Oxford. This large malaria trial is the culmination of many years of laboratory research and assessment of numerous candidate vaccines in early stage clinical trials with large numbers of collaborators.' We will utilize our more than two decades of experience in malaria vaccine testing towards successful completion of this trial'Professor Halidou Tinto, Principal Investigator of the Nanoro, Burkina Faso trial site, said:'This is a very important moment in the development of the R21 malaria vaccine candidate. We hope that the public-private partnership behind this pivotal Phase III trial will confirm the high efficacy and good safety profile seen in our phase II trial in Nanoro. The Phase II trial demonstrated high vaccine efficacy in children and I’m proud that it was done in Burkina Faso.
